Pilot study demonstrates the feasibility of EUS-VE for managing bleeding in patients with duodenal tumors, suggesting a novel approach.
Acute gastrointestinal bleeding caused by duodenal tumors remains a clinical challenge. Conventional endoscopic hemostasis has limited efficacy in preventing rebleeding, and surgical resection presents significant risks and is often not feasible. Endoscopic ultrasound-guided embolization (EUS-VE) with cyanoacrylate is widely performed for variceal bleeding, but its application to tumor-related bleeding is uncommon. In this study, we used EUS-VE for acute duodenal tumor-related bleeding. A total of 13 EUS-VE procedures were performed in 12 patients from August 2024 to December 2025. The technical success rate was 100%, and the clinical success rate within 30 days was 84.6% (11/13). Among the 12 patients, the 90-day rebleeding and mortality events occurred in 1 (8.33%) and 3 (25%) patients, respectively. Three patients (25%) developed fever after EUS-VE, including one case suspected to be procedure-related. This pilot study suggests that EUS-VE may be a feasible alternative for duodenal tumor-related bleeding. Its efficacy and safety require further validation with larger sample sizes.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: